Life Biosciences, a Boston biotech company, has shared the first human data for ER-100, an experimental gene therapy that tries to make damaged eye cells behave like younger cells. The early results, from three people with open-angle glaucoma, were presented at Eyecelerator at the American Academy of Ophthalmology meeting in New Orleans on October 8, 2026.
It’s an interesting first step for the idea of “age reversal” in medicine. It is also a very small, very early one, and that matters for how we read it.
What ER-100 is
Glaucoma damages retinal ganglion cells, the nerve cells that connect the eye to the brain. These cells don’t regenerate, so vision lost to glaucoma is usually permanent. Pressure-lowering treatment can slow the disease, but according to the company, it often keeps progressing anyway.
ER-100 takes a different route. It uses a harmless virus (AAV2) to deliver genes for three proteins, OCT4, SOX2 and KLF4, known together as OSK. These are three of the “Yamanaka factors” used in stem cell research. The idea is to reset the cells’ gene activity patterns to a more youthful state without turning them into stem cells. The genes only switch on while the patient takes the antibiotic doxycycline, which gives doctors a way to control them.
In the trial, patients get a single injection into the eye, take oral doxycycline daily for 56 days, and take a tapering course of the steroid prednisolone to limit inflammation from the virus.
What the first ER-100 results show
According to Life Biosciences, at the lowest dose (2×1011 vector genomes):
- The treatment was well tolerated in all three participants through Day 56.
- There were no dose-limiting toxicities, serious adverse events or adverse events of special interest. Other side effects were attributed to the injection procedure, the steroid or pre-existing conditions.
- Two of the three participants showed improvement on Humphrey Visual Field testing, a standard eye exam. In each of them, at least 28% of tested points improved by more than 4 decibels.
- The independent Data Safety Monitoring Board recommended moving to a threefold higher dose (6×1011 vg). The trial is ongoing.
The US FDA cleared the trial to begin in January 2026, and the first participant was dosed in June, according to Pharmacally. The study (NCT07290244) also plans to include people with NAION, a sudden form of optic nerve damage that has no approved treatment.
Why caution matters here
This is a Phase 1 trial, and its main job is to check safety, not to prove the therapy works. The numbers so far come from just three patients, at the lowest dose, followed for eight weeks. The study is open-label, which means everyone knows who got the treatment, and there is no control group to compare against.
As NAD.com noted in its coverage, the results also don’t directly show that the treatment made any cells biologically younger. Visual field tests can vary from one visit to the next, so small improvements in a handful of people need to be confirmed in larger, controlled studies. The data has been presented at a meeting and in a company release, not in a peer-reviewed paper.
There are safety questions too. Switching on reprogramming genes in human tissue is new territory, and long-term effects can only be seen with longer follow-up. Higher doses may also behave differently from the lowest one.
Two sides of the story
Supporters see a real milestone. Longevity.Technology described it as cellular rejuvenation reaching a human trial for the first time, and for a disease where lost vision is usually considered permanent, any early signal gets attention.
Sceptics would point out that the efficacy signal is far too small to draw conclusions, and that “age reversal” headlines can raise false hope among patients. Both views can be true at once.
What this could mean for patients
As a writer, I feel this is the kind of story where the headline runs far ahead of the evidence. Glaucoma is common, and many families in India know someone living with it, so I understand why “reversing vision loss” sounds exciting. But three patients and no control group is a beginning, not an answer. I’d want anyone with glaucoma to keep following their current treatment and their doctor’s advice, and to watch for the larger studies before getting hopeful.
For more context, read about how few patients get access to clinical trials, Asia’s growing biotech pipeline, and the top emerging technologies of 2026.